Introduction to global health strategy: theory and examples

Dr. Shan Soe-Lin
Dr. Robert Hecht

November 5th, 2019
Montreal, Canada
Topics for today

What is strategy
• Ideally, it is a selection of an optimized choice based on rational assessment of evidence and weighing of trade-offs

Getting strategy right is important
• With the wrong strategic choice, businesses go bankrupt, or in public health, more people get sick or die
• With optimal strategic choices, resources and outcomes are maximized

Bad strategy vs. good strategy
• Why does bad strategy happen?
• How can good strategy be developed?

Real life examples of strategy development
• Advising South Africa on how to mobilize sufficient resources to achieve HIV epidemic control
### Introduction to Pharos – using evidence to drive action

<table>
<thead>
<tr>
<th>Hepatitis C (HCV)</th>
<th>Nutrition</th>
<th>Adolescent Health</th>
<th>Country Transitions in global health</th>
</tr>
</thead>
<tbody>
<tr>
<td>Strategy and program development</td>
<td>GILEAD</td>
<td>NUTRITION INTERNATIONAL</td>
<td>KIRK HUMANITARIAN</td>
</tr>
<tr>
<td>Policy dialogue</td>
<td>Unitaid</td>
<td>TATA TRUSTS</td>
<td></td>
</tr>
<tr>
<td>Investment case development/evidence-based advocacy</td>
<td>ELEANOR CROOK FOUNDATION</td>
<td>NUTRITION INTERNATIONAL</td>
<td>JOHNS HOPKINS UNIVERSITY</td>
</tr>
</tbody>
</table>
What is strategy? A pop quiz

Which one of the statements below accurately and completely describes a strategy:

a. A world with zero preventable maternal and child deaths

b. Invest $200M dollars over the next 5 years in cost-effective maternal and child health interventions to avert 100,000 deaths

c. Reach 1 million women and children sustainably and equitably with lifesaving interventions

d. Achieve world peace
Strategy is: a set of **guiding principles** that, when communicated and adopted in the organization, generates a **desired pattern of decision making**.

A strategy is therefore about how an organization should **make decisions and allocate resources** in order to accomplish **key objectives**.

A good strategy provides a **clear roadmap**, consisting of a guiding plan, that defines the **actions** people in the business should take (and not take) and the things they should **prioritize** (and not prioritize) to achieve desired goals.

*Michael Watkins*
Strategy is just one component of an overall strategic direction.

1. **Vision**
   - Motivation

2. **Mission**
   - “What” will be achieved

3. **Strategy**
   - How resources should be allocated to achieve mission

4. **Roadmap**
   - Resources, partners, timelines, sequence to implement
Good strategy enhances competitiveness and outcomes

Successful strategy depends upon the ability to **foresee** the future consequences of present initiatives
Where do we start to build a strategy?

External forces

1. Goal
2. Plan
3. Resources
## Good strategy vs. bad strategy

<table>
<thead>
<tr>
<th>Jack Welch: “reach for what appears to be the impossible”</th>
<th>Wayne Gretzky: “skate to where the puck is going to be” [and be ready to shoot]</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Develop a <strong>vision</strong> to be the best or the leading or the mightiest</td>
<td>1. <strong>Develop a diagnosis</strong> to simplify complexity and identify the most critical obstacles</td>
</tr>
<tr>
<td>2. Develop a <strong>mission</strong> statement of the purpose of the organization, incorporating sustainability or other popular elements</td>
<td>2. <strong>Define a guiding strategic plan:</strong> develop and test scenarios, and define an overall approach to overcome the problems identified in the diagnosis and maximize outcomes</td>
</tr>
<tr>
<td>3. List non-controversial <strong>values</strong> such as integrity, respect and excellence</td>
<td>3. <strong>Identify and implement coherent actions:</strong> Coordinated steps to implement the guiding strategic plan</td>
</tr>
<tr>
<td>4. Create some <strong>goals</strong> but call them strategies.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Bad</th>
<th>Good</th>
</tr>
</thead>
</table>

## Three basic elements of good strategy development

<table>
<thead>
<tr>
<th></th>
<th>Diagnosis and assessment</th>
<th>Guiding policy (strategic plan)</th>
<th>Coherent actions (roadmap)</th>
</tr>
</thead>
</table>
| 1 | • What are the future opportunities?  
   • What are the looming threats/risks?  
   • Are we ready for change?  
   • What are we good at?  
   • What are our weaknesses?  
   • What is our risk tolerance?  | • Develop set of options based on diagnosis  
   • Evaluate options based on objective criteria  
   • Set strategic plan based on clear understanding of opportunities, risks, tradeoffs | • Define what we will need to do to be ready to implement the guiding strategy  
   • What we will need in terms of financial, human, & technical resources  
   • Monitor execution and course correct |
Failures in business come from failures to get one or more of the three elements right:

1. **Kodak** → **Fujifilm**
   - Failed to diagnose and adapt to new digital marketplace

2. **Sears** → **Home Depot**
   - Pursued wrong strategy to merge with Kmart

3. **Blockbuster** → **Netflix**
   - Incoherent action: reversed decision to invest in online and went back to retail
Similarly, failures in global health come from failures to get one or more of the three elements of good strategy right

<table>
<thead>
<tr>
<th>Fail</th>
<th>Consequence</th>
<th>Reason</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inadequate response to Ebola outbreak in 2014</td>
<td>&gt;11,000 deaths, $53B cost to economies</td>
<td>Poor diagnosis of importance of cultural factors/obstacles, weak guiding principles, slow response</td>
</tr>
<tr>
<td>America’s failure to control gun violence</td>
<td>39,000 deaths per year, $229B annual cost</td>
<td>Policy and political will failure, poor diagnosis</td>
</tr>
<tr>
<td>Iatrogenic HCV epidemic in Egypt</td>
<td>15% seropositive, $4B annual economic cost</td>
<td>Wrong action to re-use needles as part of schistosomiasis control campaign</td>
</tr>
</tbody>
</table>
# Good strategy development in real life

## Diagnosis and analyses
- Interviews with internal and external experts
- Epidemiological analyses
- Assessment of organizational capabilities
- Competitive landscape
- Development and testing of options

## Strategic plan
- Rationalization of current needs against future opportunities
- Rationalization of risks vs potential
- Development and assessment of options
- Setting of strategic direction
- Calculation of return on investment

## Roadmap
- Determination of additional resources, including financial, human, and technical that will be needed to implement
- Timeline and sequence of implementation
- Milestones
- Framework for evaluation
Examples of strategic questions that we’ve helped our clients solve:

How to:

• Justify new investments in national scale up of programs to eliminate Hepatitis B and C in 6 countries of Asia and Africa

• Help countries plan for and achieve self-sufficiency in managing their own disease control programs after donors withdraw support

• Make the case to mobilize the resources needed to reach the World Health Assembly targets to end malnutrition

• Make the case to replenish the Global Fund’s $15B target for AIDS, TB, and Malaria

• Create forward-strategies for global health organizations to be more effective in how they allocate their funding
Revisit the pop quiz

Which one of the statements below accurately and completely describes a strategy:

a. A world with zero preventable maternal and child deaths

b. Invest $200M dollars over the next 5 years in cost-effective maternal and child health interventions to avert 100,000 deaths

c. Reach 1 million women and children sustainably and equitably with lifesaving interventions

d. Achieve world peace
Strategy and Analysis in Action -- South Africa

Aids2031 and the HIV/TB Investment Case feature:
- Problem Identification
- Diagnosis/Analysis
- Strategic Planning
- Development of an Action Roadmap
- Adoption and Implementation of the Roadmap
- Monitoring and Evaluation
- Mid-course Readjustment

Also combine data and tools (you learn at McGill) from: epidemiology, disease modeling, costing and financial analysis, political analysis and facilitation of consensus building
THE LONG RUN
COSTS AND FINANCING
OF HIV/AIDS IN SOUTH AFRICA

Prepared by the
Centre for Economic Governance and AIDS in Africa
and
Results for Development Institute

JUNE 2010
Overview of aids2031-South Africa

• South Africa project carried out during 2008-2010

• Linked to a global multi-country assessment of AIDS costs and financing options

• Sponsored and guided by SA National Steering Committee

• High level meetings with the SA Health Minister and the South Africa AIDS Council chaired by the Vice-President of SA

• Technical work by a joint South African and International team (CEGAA and Results for Development)

• Part of the larger aids2031 project led by Peter Piot, former Executive Director of UNAIDS
The Problem

South Africa is facing a major and mounting financial challenge as it strives to respond to the HIV/AIDS epidemic in the country. South Africa has 5.7 million people currently infected with the HIV virus, the largest number in the world, and half a million adults and children are becoming newly infected each year (UNAIDS, 2009). The funding needed to respond to HIV/AIDS on three critical fronts—for prevention, treatment, and care of orphans and others affected by AIDS—is continuing to escalate rapidly, especially as hundreds of thousands of additional South Africans enter antiretroviral treatment (ART) programmes. This situation poses huge financial dangers and risks for the country, particularly at a time when South Africa is feeling the negative effects of the global economic recession and is struggling to maintain its government budget for a wide range of pressing needs including education, housing, job creation, and other health priorities beyond HIV/AIDS.
The legacy of neglect and inaction

(from a 2015 paper by the top four SA AIDS officials)

Abstract  For the past 25 years, South Africa has had to deal with the inexorable and monumental rise of HIV. From one or two isolated cases, in the late 1980s, South Africa now has an estimated 6.4 million people infected with HIV, with high rates of concomitant tuberculosis, which will profoundly affect the country for decades to come. For nearly 10 years, the South African government’s response to the HIV epidemic was described as denialist, which was estimated to have resulted in the deaths of 330,000 people because lifesaving antiretroviral therapy (ART) was not provided (Chigwedere et al. J Acquir Immune Defic Syndr. 49:410–15, 2008;)

(from a 2016 paper In Science on the eve of the Durban conference)

When it last hosted this international gathering in 2000, then-President Thabo Mbeki and his health minister questioned whether HIV even causes AIDS, triggering widespread outrage. At the time, only the wealthiest South Africans had access to ARVs, which cost about $5000 per person for an annual supply.
The Strategic Issues

• What combination of services (prevention and treatment) can turn the tide of the epidemic? What impact will they have?

• How much money will be needed for a strong and effective national HIV/AIDS program?

• How can available financial resources be used more efficiently?

• Who will pay for these critical HIV/AIDS activities in the future (government, private sector, donors)?
South Africa: Scenarios for the Future of AIDS

The Drivers:

- Political will (higher/lower)
- Pace of social norm change (fast/slow)
- Outlook (emergency/long-term)
- Financial capacity (higher/lower)
- Implementation capacity (constrained/unconstrained)
Scenario 1: National Strategic Plan (NSP)

Political will to achieve universal access is strong; short term outlook; few implementation constraints

Rapid scaling-up of prevention & treatment over short period, then maintenance of levels

- Achieving NSP targets for 2011-12 and sustain
- Treatment - old regime at 200 CD4 threshold
- PMTCT single dose till 2009, replaced by dual therapy
- Early pediatric ART from 2009
- No Male Circumcision
Scenario 2 - Expanded NSP

AIDS seen as a long-term problem: greater focus on interventions to reduce vulnerability; slower but more sustained scale up to higher levels; no long-term funding constraints

Achievement of NSP (& extra) targets by 2021

- ART - new regime & CD4 threshold = 350
- VMMC introduced 2010, reaching 60%
- Expanded workplace programmes, education, behaviour change
- Mobilization and higher coverage for Key Populations: SW, MSM
- Expanded efforts for out-of-school youths
- Programs to reduce violence against women
Scenario 3 - Hard Choices

Resources are limited; focus on scaling up to the most cost-effective prevention interventions; other prevention and social programs reduced; targets achieved by 2015

• Increased coverage for youth in school, condoms, male circumcision, SW & MSMs, STI treatment
• Maintaining current coverage for HCT, child grants
• Reduction below NSP targets for mass media, youth-out of-school, workplace, HBC, palliative care, food parcels, uniforms & other mitigation
• Same ART effort as under NSP
South Africa: Adults Receiving ART, 2000-2031

Millions

Baseline
Narrow NSP
Expanded NSP
Hard Choices
South Africa: Total AIDS Funding Required, 2009-2031 (R billions)
## Summary of Main Scenario Results

<table>
<thead>
<tr>
<th></th>
<th>Status Quo/Baseline</th>
<th>Expanded NSP</th>
<th>Narrow NSP</th>
<th>Hard Choices</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total new infections 2009-31 (millions)</td>
<td>11</td>
<td>5</td>
<td>8</td>
<td>6</td>
</tr>
<tr>
<td>New Infections in 2031 (thousands)</td>
<td>500</td>
<td>180</td>
<td>360</td>
<td>230</td>
</tr>
<tr>
<td>Adult prevalence 2031 (percent)</td>
<td>17</td>
<td>10</td>
<td>15</td>
<td>11.5</td>
</tr>
<tr>
<td>Total AIDS deaths 2009-31 (millions)</td>
<td>8.1</td>
<td>4.4</td>
<td>5.9</td>
<td>5.8</td>
</tr>
<tr>
<td>Number of ART patients 2021 (m)</td>
<td>1.8</td>
<td>3.0</td>
<td>2.7</td>
<td>2.6</td>
</tr>
<tr>
<td>Total cost 2009-31 (R billions)</td>
<td>NA</td>
<td>765</td>
<td>658</td>
<td>598</td>
</tr>
<tr>
<td>Total annual cost in 2021 (R billions)</td>
<td>NA</td>
<td>39.3</td>
<td>32.3</td>
<td>29.7</td>
</tr>
<tr>
<td>Of which ART in 2021 (percent)</td>
<td>NA</td>
<td>65</td>
<td>70</td>
<td>74</td>
</tr>
</tbody>
</table>
Key Findings

- SA’s epidemic is deeply entrenched: past and current dynamics make reversal extremely difficult over the next two decades.

- Under scenarios studied, there will still be a substantial number of new infections and prevalence will remain high for the next two decades (>10% of adults) -- in the absence of a technology breakthrough or radical behaviour change.

- Nevertheless, SA faces choices today that will have large positive (or negative) consequences for future costs and health outcomes.
Wise Choices Matter: SA at the Crossroads

- If resources are limited, wise policy decisions on prevention can make an important difference: Hard Choices averts more infections & costs less than Narrow NSP

- With a more robust budget and willingness to tackle social issues and pursue a maximum prevention strategy, the rate of new infections can be curbed substantially
  - Under Expanded NSP approach, national incidence reduction targets can be achieved - but at a higher cost
  - Stronger prevention now will have important knock-on effects on lowering treatment costs in the long run
Critical Choices in Financing The Response to the Global HIV/AIDS Pandemic

Costs could rise to $1.30 million a year by 2031—unless the world takes dramatic steps to forestall the worst outcomes.

By Robert Hecht, Lois Ballenger, John Snow, William McGoogan, Jacemine Mulhia, Cathleen Eman Medaen, and Daniel de Ferrari

ABSTRACT The AIDS pandemic will enter its fifth year in 2015. Despite much progress, there are still three million infected people worldwide, and 2.2 million adults and children newly infected in 2013. Without a change in approach, a major pandemic will still be with us in 2015. Mobilization continues for the AIDS 2015 project, suggesting the funding needed to be deployed in countries to address the pandemic could reach $1 billion annually by 2015. Beyond these three current key issues, more than one million people will still be newly infected in 2015. How countries will respond under these circumstances will be the key issue. However, unless a clear consensus emerges on how to effectively and efficiently allocate funds to reach and engage more people, funding efforts will not yield the desired results. Countries with successful environments, policies, and resources are more likely to achieve the desired results. Financial laws and regulations need to be in place to ensure effective and efficient use of funds.

The Long-Run Costs and Financing of HIV/AIDS in Cambodia

Prepared by the Centre for Economic Governance and AIDS in Africa and Results for Development Institute

The Long-Term Costs of HIV/AIDS in South Africa

Prepared by the Centre for Economic Governance and AIDS in Africa and Results for Development Institute

Results for Development Institute
Six years later....

Also from the article by the SA AODS leaders

Heywood (2004). However, the story of the HIV and AIDS response in South Africa over the past 5 years is one of great progress after almost a decade of complex and tragic denialism that united civil society in a way not seen since the opposition to apartheid. Today, South Africa can boast of close to 3 million people on ART, by far the largest number in the world. Prevention efforts appear to be yielding results but

trum in older age groups. As a result of the massive increase in access to ART after 2004 and particularly after 2008 as political will towards the HIV ART programme improved, there has been a marked increase in life expectancy, from 56 to 61 years in the period 2009–2012 alone; the aggressive expansion of the prevention of mother to child transmission (PMTCT) to HIV-positive pregnant women has been accompanied by dramatic decrease in HIV transmission to infants; and a 25% decrease in child and infant mortality rates in the period 2009–2012. This progress in access is significantly due
More on the turnaround...

And from the Science paper in 2016

But by the end of 2015, the price had dropped to $100, and 3.4 million HIV-infected South Africans were receiving ARVs—more than in any other country in the world. South Africa, in fact, consumes the same amount of the life-saving drugs as Asia and the Pacific, North America, and western and central Europe combined.

As a result, life expectancy jumped 9 years between 2005, when ARVs started to become widely available, and 2014. The country has pioneered innovative ways to deliver the drugs and help people stay on them. And South Africa’s strong cadre of HIV/AIDS investigators has made the country a hub of cutting-edge basic research and clinical trials.
Financing South Africa’s HIV Response

Aaron Motsoaledi
Minister of Health, South Africa

Mcebisi Hubert Jonas
Deputy Minister of Finance, South Africa

Michel Sidibé
Executive Director, UNAIDS

Deborah Birx
Global AIDS Coordinator, United States

Mark Dybul
Executive Director, The Global Fund

Moderated by
Mia Malan
Director and Editor
Bhekisisa: M&G Centre for Health Journalism
South Africa

With technical introduction from
Robert Hecht
Results for Development Institute

Organized by
National Department of Health
South Africa
In partnership with
UNAIDS
Results for Development Institute
Financing South Africa’s HIV Response: Much to Celebrate, Much Left to Do

Robert Hecht
Results for Development Institute
Durban, South Africa
19 July 2016
Satellite Symposium at the 21st International AIDS Conference
**Why South Africa matters so much...**

*6.8M* HIV-infected people live in **South Africa**, more than any other country

<table>
<thead>
<tr>
<th>Country</th>
<th>HIV-infected people (millions)</th>
</tr>
</thead>
<tbody>
<tr>
<td>South Africa</td>
<td>6.8</td>
</tr>
<tr>
<td>Nigeria</td>
<td>3.5</td>
</tr>
<tr>
<td>India</td>
<td>2.1</td>
</tr>
<tr>
<td>Moz/Kenya/Uganda</td>
<td>1.5</td>
</tr>
<tr>
<td>Zim/Tanzania</td>
<td>1.4</td>
</tr>
</tbody>
</table>

1/6 of all new infections occur in **South Africa**... About 340,000 new infections per year

**Most number of PLHIV**

**Most new infections**

**Most patients on treatment**

---

Data notes: all data in the left and right panels are reported for 2015 at aidsinfo.unaids.org. South Africa’s new infections in the center panel is reported in the HIV and TB Investment Case for 2013. The total number of new infections globally for that year (2.1 million) comes from aidsinfo.unaids.org.
South Africa started late but has since made dramatic progress

The decline in new infections came later in South Africa...

...but coverage has accelerated rapidly

Data notes: these data come from aidsinfo.unaids.org.
Increased financing has propelled and underpinned the growth in coverage

South Africa is the largest spender among LMICs...

...and finances the majority of HIV services with domestic resources

Data notes: these data come from aidsinfo.unaids.org.
The work is not done: despite successes, there are still major challenges to be addressed

Significant financial gaps remain before epidemic control can be achieved

Increased HIV spending risks crowding out other health priorities

Data notes: the top panel is a recreation of Figure 1 in the South African HIV and TB Investment Case. Data in the bottom panel come from R4D’s analysis of South Africa’s Estimates of National and Provincial Expenditure.
**How will South Africa keep funding its HIV scale-up?**

**Strategies to get the most out of every Rand**

<table>
<thead>
<tr>
<th>Lower drug and procurement costs</th>
<th>Enhance workforce efficiency</th>
<th>Maximize program effectiveness &amp; efficiency</th>
<th>Increase sustainability</th>
<th>Improve coordination</th>
</tr>
</thead>
<tbody>
<tr>
<td>Procurement and market shaping, especially for diagnostics and 2\textsuperscript{nd}/3\textsuperscript{rd} line drugs</td>
<td>Downward task shifting</td>
<td>Adherence counseling, community and family support</td>
<td>Sustain the effort financially with stable long-term domestic sources – integration with PHC, incorporation in NHI</td>
<td>Avoid waste and unplanned gaps – better coordination and carefully designed transitions among Government and Partners</td>
</tr>
</tbody>
</table>
The Strategy Cycle Continues
“When people are determined they can overcome anything.”

“It always seems impossible until it’s done.”

-Nelson Mandela